Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications
AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zheji...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 18; no. 24; pp. 3167 - 3172 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Co., Limited
28.06.2012
|
Subjects | |
Online Access | Get full text |
ISSN | 1007-9327 2219-2840 2219-2840 |
DOI | 10.3748/wjg.v18.i24.3167 |
Cover
Abstract | AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zhejiang University.The hospital has 2300 beds and 2.5 million outpatient visits annually.Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011.Concomitant use of proton-pump inhibitors(PPIs),histamine 2-receptor antagonists(H2RA) and mucoprotective drugs(MPs) were analyzed.A defined daily dose(DDD) methodology was applied to each MP.A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs(NSAIDs),corticosteroids and clopidogrel and warfarin] or intestinal protective drugs(misoprostol,rebamipide,teprenone and gefarnate).Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records.The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.RESULTS:Prescriptions for aspirin users receiving PPIs,H2RA and MPs(n = 1039) accounted for only 3.46% of total aspirin prescriptions(n = 30 015).The ratios of coadministration of aspirin/PPI,aspirin/H2RA,aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%,0.12%,0.40% and 0.12%,respectively.No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs,H2RA or MPs.The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs(2.82% vs 0.40%,P 〈 0.05) and aspirin/H2RA(2.82% vs 0.12%,P 〈 0.05).The values of DDDs of MPs in descending order were as follows:gefarnate,hydrotalcite 〉 teprenone 〉 sucralfate oral suspension 〉 L-glutamine and sodium gualenate granules 〉 rebamipide 〉 sucralfate chewable tablets.The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows:rebamipide(0.47%),teprenone(0.91%),L-glutamine and sodium gualenate granules(0.92%),gefarnate(0.31%),hydrotalcite(1.00%) and sucralfate oral suspension(0.13%).Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were:rebamipide(0.010%),PPI/rebamipide(0.027%),teprenone(0.11%),PPI/teprenone(0.037%),gefarnate(0.017%),and PPI/gefarnate(0.013%).No prescriptions were found containing coadministration of aspirin and other NSAIDs.Among the 3196 prescriptions containing aspirin/clopidogrel,3088(96.6%) prescriptions did not contain any GI protective medicines.Of the 389 prescriptions containing aspirin/corticosteroids,236(60.7%) contained no GI protective medicines.None of the prescriptions using aspirin/warfarin(n = 22) contained GI protective medicines.Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin.The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin,respectively.CONCLUSION:The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications.Actions should be taken to address this issue. |
---|---|
AbstractList | AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zhejiang University.The hospital has 2300 beds and 2.5 million outpatient visits annually.Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011.Concomitant use of proton-pump inhibitors(PPIs),histamine 2-receptor antagonists(H2RA) and mucoprotective drugs(MPs) were analyzed.A defined daily dose(DDD) methodology was applied to each MP.A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs(NSAIDs),corticosteroids and clopidogrel and warfarin] or intestinal protective drugs(misoprostol,rebamipide,teprenone and gefarnate).Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records.The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.RESULTS:Prescriptions for aspirin users receiving PPIs,H2RA and MPs(n = 1039) accounted for only 3.46% of total aspirin prescriptions(n = 30 015).The ratios of coadministration of aspirin/PPI,aspirin/H2RA,aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%,0.12%,0.40% and 0.12%,respectively.No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs,H2RA or MPs.The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs(2.82% vs 0.40%,P 〈 0.05) and aspirin/H2RA(2.82% vs 0.12%,P 〈 0.05).The values of DDDs of MPs in descending order were as follows:gefarnate,hydrotalcite 〉 teprenone 〉 sucralfate oral suspension 〉 L-glutamine and sodium gualenate granules 〉 rebamipide 〉 sucralfate chewable tablets.The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows:rebamipide(0.47%),teprenone(0.91%),L-glutamine and sodium gualenate granules(0.92%),gefarnate(0.31%),hydrotalcite(1.00%) and sucralfate oral suspension(0.13%).Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were:rebamipide(0.010%),PPI/rebamipide(0.027%),teprenone(0.11%),PPI/teprenone(0.037%),gefarnate(0.017%),and PPI/gefarnate(0.013%).No prescriptions were found containing coadministration of aspirin and other NSAIDs.Among the 3196 prescriptions containing aspirin/clopidogrel,3088(96.6%) prescriptions did not contain any GI protective medicines.Of the 389 prescriptions containing aspirin/corticosteroids,236(60.7%) contained no GI protective medicines.None of the prescriptions using aspirin/warfarin(n = 22) contained GI protective medicines.Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin.The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin,respectively.CONCLUSION:The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications.Actions should be taken to address this issue. To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications. A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients. Prescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively. The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue. AIM: To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications. METHODS: A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients. RESULTS: Prescriptions for aspirin users receiving PPIs, H2RA and MPs ( n = 1039) accounted for only 3.46% of total aspirin prescriptions ( n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin ( n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively. CONCLUSION: The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue. To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications.AIMTo investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined protective medications.A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.METHODSA retrospective drug utilization study was conducted in the 2nd Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2300 beds and 2.5 million outpatient visits annually. Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011. Concomitant use of proton-pump inhibitors (PPIs), histamine 2-receptor antagonists (H2RA) and mucoprotective drugs (MPs) were analyzed. A defined daily dose (DDD) methodology was applied to each MP. A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs (NSAIDs), corticosteroids and clopidogrel and warfarin] or intestinal protective drugs (misoprostol, rebamipide, teprenone and gefarnate). Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records. The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.Prescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively.RESULTSPrescriptions for aspirin users receiving PPIs, H2RA and MPs (n = 1039) accounted for only 3.46% of total aspirin prescriptions (n = 30 015). The ratios of coadministration of aspirin/PPI, aspirin/H2RA, aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%, 0.12%, 0.40% and 0.12%, respectively. No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs, H2RA or MPs. The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs (2.82% vs 0.40%, P < 0.05) and aspirin/H2RA (2.82% vs 0.12%, P < 0.05). The values of DDDs of MPs in descending order were as follows: gefarnate, hydrotalcite > teprenone > sucralfate oral suspension > L-glutamine and sodium gualenate granules > rebamipide > sucralfate chewable tablets. The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows: rebamipide (0.47%), teprenone (0.91%), L-glutamine and sodium gualenate granules (0.92%), gefarnate (0.31%), hydrotalcite (1.00%) and sucralfate oral suspension (0.13%). Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were: rebamipide (0.010%), PPI/rebamipide (0.027%), teprenone (0.11%), PPI/teprenone (0.037%), gefarnate (0.017%), and PPI/gefarnate (0.013%). No prescriptions were found containing coadministration of aspirin and other NSAIDs. Among the 3196 prescriptions containing aspirin/clopidogrel, 3088 (96.6%) prescriptions did not contain any GI protective medicines. Of the 389 prescriptions containing aspirin/corticosteroids, 236 (60.7%) contained no GI protective medicines. None of the prescriptions using aspirin/warfarin (n = 22) contained GI protective medicines. Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin. The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin, respectively.The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue.CONCLUSIONThe prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications. Actions should be taken to address this issue. |
Author | Ling-Ling Zhu Ling-Cheng Xu Yan Chen Quan Zhou Su Zeng |
AuthorAffiliation | Geriatric Ward, the 2nd Affiliated Hospital,School of Medicine, Zhejiang University, Hangzhou 310009,Zhejiang Province, China Department of Pharmacy, the2nd Affiliated Hospital, School of Medicine, Zhejiang Univer-sity, Hangzhou 310009, Zhejiang Province, China Department of Gastroenterology, the 2nd AffiliatedHospital. School of Medicine, Zhejiang University, Hangzhou310009, Zhejiang Province, China Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang Uni- versity, Hangzhou 310058, Zhejiang Province, China |
Author_xml | – sequence: 1 givenname: Ling-Ling surname: Zhu fullname: Zhu, Ling-Ling |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22791953$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kT1v2zAQhokiReOk3TsV6tZFLskjRWkpUAT9AgK0QzITFEXJZ8ikQko28u_DNE7QZshCDvd-4O45Iyc-eEfIe0bXoET9-bAd1ntWr5GLNbBKvSIrzllT8lrQE7JilKqyAa5OyVlKW0o5gORvyCnnqmGNhBXBPyHEwhxMdN6lVIS-mKLbOz-jHwqTJozoS_TdYl1XDCbNMaCfXcpzMxbot0u8LQ44bwobdi36rJpimJ2dce-KnevQmhmDT2_J696Myb07_ufk-vu3q4uf5eXvH78uvl6WVnA-lxVjTQ99fquWCyEALFSK21YaKaXqu7bvHJVOtcI0QlQ221oJyqgOLG0onJMvD7nT0uZ6m1eJZtRTxJ2JtzoY1P9PPG70EPYaoK4AWA74dAyI4WbJm-odJuvG0XgXlqQZ5aIBAbXM0g__dj2VPN43C6oHgY0hpeh6bXH-e49cjWPO0vcgdQapM0idQep7kNlInxkfs1-wfDxaNsEPN5nfk0dwSRsOFO4A5q-xBQ |
CitedBy_id | crossref_primary_10_1007_s40278_021_94529_1 crossref_primary_10_4330_wjc_v15_i8_375 crossref_primary_10_1155_2019_6532876 crossref_primary_10_1111_jphp_13227 crossref_primary_10_4103_pm_pm_333_21 crossref_primary_10_3810_pgm_2014_01_2728 crossref_primary_10_1016_j_cpcardiol_2017_01_006 crossref_primary_10_3389_fmed_2021_647494 crossref_primary_10_2174_1381612826666201102101758 crossref_primary_10_1007_s12272_018_1068_5 crossref_primary_10_1097_CRD_0000000000000174 crossref_primary_10_1016_j_amjmed_2012_10_026 crossref_primary_10_1371_journal_pone_0131558 crossref_primary_10_1016_j_ajpc_2022_100363 crossref_primary_10_1016_j_cej_2020_127176 crossref_primary_10_1007_s40261_017_0519_y |
ContentType | Journal Article |
Copyright | 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012 |
Copyright_xml | – notice: 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012 |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.3748/wjg.v18.i24.3167 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications |
EISSN | 2219-2840 |
EndPage | 3172 |
ExternalDocumentID | PMC3386331 22791953 10_3748_wjg_v18_i24_3167 42509230 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 W91 WFFXF XSB ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c422t-6119f3f1196b244433c3672cb5a5557fdbfde05e7b4a9446cc42b537a7d3c0903 |
ISSN | 1007-9327 2219-2840 |
IngestDate | Thu Aug 21 18:34:26 EDT 2025 Fri Jul 11 00:08:15 EDT 2025 Mon Jul 21 06:05:10 EDT 2025 Thu Apr 24 22:58:38 EDT 2025 Tue Jul 01 03:21:56 EDT 2025 Wed Feb 14 10:46:24 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 24 |
Keywords | Small bowel injury Drug utilization Prescribing patterns Histamine 2-receptor antagonists Defined daily dose Low-dose aspirin Combined medications Proton-pump inhibitors Gastrointestinal injury Mucoprotective drugs |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c422t-6119f3f1196b244433c3672cb5a5557fdbfde05e7b4a9446cc42b537a7d3c0903 |
Notes | 14-1219/R AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with combined protective medications.METHODS:A retrospective drug utilization study was conducted in the 2nd Affiliated Hospital,School of Medicine,Zhejiang University.The hospital has 2300 beds and 2.5 million outpatient visits annually.Data mining was performed on all aspirin prescriptions for outpatients and emergency patients admitted in 2011.Concomitant use of proton-pump inhibitors(PPIs),histamine 2-receptor antagonists(H2RA) and mucoprotective drugs(MPs) were analyzed.A defined daily dose(DDD) methodology was applied to each MP.A further investigation was performed in aspirin users on combination use of GI injurious medicines [non-steoid anti-inflammatory drugs(NSAIDs),corticosteroids and clopidogrel and warfarin] or intestinal protective drugs(misoprostol,rebamipide,teprenone and gefarnate).Data of major bleeding episodes were derived from medical records and adverse drug reaction monitoring records.The annual incidence of major GI bleeding due to low-dose aspirin was estimated for outpatients.RESULTS:Prescriptions for aspirin users receiving PPIs,H2RA and MPs(n = 1039) accounted for only 3.46% of total aspirin prescriptions(n = 30 015).The ratios of coadministration of aspirin/PPI,aspirin/H2RA,aspirin/MP and aspirin/PPI/MP to the total aspirin prescriptions were 2.82%,0.12%,0.40% and 0.12%,respectively.No statistically significant difference was observed in age between patients not receiving any GI protective medications and patients receiving PPIs,H2RA or MPs.The combined medication of aspirin and PPI was used more frequently than that of aspirin and MPs(2.82% vs 0.40%,P 〈 0.05) and aspirin/H2RA(2.82% vs 0.12%,P 〈 0.05).The values of DDDs of MPs in descending order were as follows:gefarnate,hydrotalcite 〉 teprenone 〉 sucralfate oral suspension 〉 L-glutamine and sodium gualenate granules 〉 rebamipide 〉 sucralfate chewable tablets.The ratio of MP plus aspirin prescriptions to the total MP prescriptions was as follows:rebamipide(0.47%),teprenone(0.91%),L-glutamine and sodium gualenate granules(0.92%),gefarnate(0.31%),hydrotalcite(1.00%) and sucralfate oral suspension(0.13%).Percentages of prescriptions containing aspirin and intestinal protective drugs among the total aspirin prescriptions were:rebamipide(0.010%),PPI/rebamipide(0.027%),teprenone(0.11%),PPI/teprenone(0.037%),gefarnate(0.017%),and PPI/gefarnate(0.013%).No prescriptions were found containing coadministration of aspirin and other NSAIDs.Among the 3196 prescriptions containing aspirin/clopidogrel,3088(96.6%) prescriptions did not contain any GI protective medicines.Of the 389 prescriptions containing aspirin/corticosteroids,236(60.7%) contained no GI protective medicines.None of the prescriptions using aspirin/warfarin(n = 22) contained GI protective medicines.Thirty-five patients were admitted to this hospital in 2011 because of acute hemorrhage of upper digestive tract induced by low-dose aspirin.The annual incidence rates of major GI bleeding were estimated at 0.25% for outpatients taking aspirin and 0.5% for outpatients taking aspirin/warfarin,respectively.CONCLUSION:The prescribing pattern of low-dose aspirin revealed a poor awareness of preventing GI injury with combined protective medications.Actions should be taken to address this issue. Low-dose aspirin; Gastrointestinal injury;Small bowel injury; Drug utilization; Prescribing patterns;Combined medications; Proton-pump inhibitors; Hista-mine 2-receptor antagonists; IVlucoprotective drugs; De-fined daily dose ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: Zhu LL and Zhou Q conceived and designed research; Xu LC collected data from the Hospital Information System; Zhou Q and Chen Y performed literature review and data analysis; and Zhou Q and Zeng S wrote the paper. Correspondence to: Quan Zhou, PhD, Professor, Clinical Pharmacy Specialist, Department of Pharmacy, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang Province, China. zhouquan142602@zju.edu.cn Telephone: +86-571-87784615 Fax: +86-571-87022776 |
OpenAccessLink | https://www.wjgnet.com/1007-9327/full/v18/i24/3167.htm |
PMID | 22791953 |
PQID | 1024934385 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3386331 proquest_miscellaneous_1024934385 pubmed_primary_22791953 crossref_citationtrail_10_3748_wjg_v18_i24_3167 crossref_primary_10_3748_wjg_v18_i24_3167 chongqing_primary_42509230 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-06-28 |
PublicationDateYYYYMMDD | 2012-06-28 |
PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2012 |
Publisher | Baishideng Publishing Group Co., Limited |
Publisher_xml | – name: Baishideng Publishing Group Co., Limited |
References | 21464720 - Eur J Gastroenterol Hepatol. 2011 May;23(5):396-404 18995219 - Clin Gastroenterol Hepatol. 2008 Nov;6(11):1279-82 19968611 - Scand J Gastroenterol. 2010 Mar;45(3):292-8 21072898 - World J Gastroenterol. 2010 Nov 14;16(42):5342-6 22093203 - Am Heart J. 2011 Nov;162(5):870-4 20588029 - Digestion. 2010;82(3):167-72 18477341 - Am J Gastroenterol. 2008 May;103(5):1097-103 10792114 - Aliment Pharmacol Ther. 2000 May;14(5):529-34 21130762 - Eur J Pharmacol. 2011 Feb 10;652(1-3):121-5 20562062 - Eur J Med Res. 2010 May 18;15(5):220-4 22171147 - World J Gastroenterol. 2011 Dec 14;17(46):5117-22 19222098 - World J Gastroenterol. 2009 Feb 14;15(6):727-31 21357821 - Circulation. 2011 Mar 15;123(10):1108-15 20858483 - Eur J Pharmacol. 2010 Dec 15;649(1-3):314-9 20664727 - J Clin Biochem Nutr. 2010 Jul;47(1):27-31 21699808 - Clin Gastroenterol Hepatol. 2011 Sep;9(9):762-768.e6 19794936 - J Clin Biochem Nutr. 2009 Sep;45(2):248-53 19446158 - Clin Ther. 2009 Apr;31(4):849-61 20410834 - J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7 19844108 - Digestion. 2009;80(4):260-6 21245996 - World J Gastroenterol. 2011 Jan 14;17(2):226-30 16948802 - Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908 19192936 - Drugs. 2009;69(1):51-69 7098146 - Jpn J Pharmacol. 1982 Apr;32(2):299-306 21387691 - Nihon Rinsho. 2011 Feb;69(2):369-75 21499703 - J Gastroenterol. 2011 Jun;46(6):724-35 |
References_xml | – reference: 21699808 - Clin Gastroenterol Hepatol. 2011 Sep;9(9):762-768.e6 – reference: 19968611 - Scand J Gastroenterol. 2010 Mar;45(3):292-8 – reference: 21357821 - Circulation. 2011 Mar 15;123(10):1108-15 – reference: 21387691 - Nihon Rinsho. 2011 Feb;69(2):369-75 – reference: 19794936 - J Clin Biochem Nutr. 2009 Sep;45(2):248-53 – reference: 16948802 - Aliment Pharmacol Ther. 2006 Sep 15;24(6):897-908 – reference: 20562062 - Eur J Med Res. 2010 May 18;15(5):220-4 – reference: 22093203 - Am Heart J. 2011 Nov;162(5):870-4 – reference: 19844108 - Digestion. 2009;80(4):260-6 – reference: 10792114 - Aliment Pharmacol Ther. 2000 May;14(5):529-34 – reference: 20588029 - Digestion. 2010;82(3):167-72 – reference: 20410834 - J Cardiovasc Pharmacol. 2010 Jul;56(1):91-7 – reference: 21130762 - Eur J Pharmacol. 2011 Feb 10;652(1-3):121-5 – reference: 7098146 - Jpn J Pharmacol. 1982 Apr;32(2):299-306 – reference: 18477341 - Am J Gastroenterol. 2008 May;103(5):1097-103 – reference: 19446158 - Clin Ther. 2009 Apr;31(4):849-61 – reference: 18995219 - Clin Gastroenterol Hepatol. 2008 Nov;6(11):1279-82 – reference: 21464720 - Eur J Gastroenterol Hepatol. 2011 May;23(5):396-404 – reference: 22171147 - World J Gastroenterol. 2011 Dec 14;17(46):5117-22 – reference: 20664727 - J Clin Biochem Nutr. 2010 Jul;47(1):27-31 – reference: 19222098 - World J Gastroenterol. 2009 Feb 14;15(6):727-31 – reference: 21245996 - World J Gastroenterol. 2011 Jan 14;17(2):226-30 – reference: 21072898 - World J Gastroenterol. 2010 Nov 14;16(42):5342-6 – reference: 21499703 - J Gastroenterol. 2011 Jun;46(6):724-35 – reference: 20858483 - Eur J Pharmacol. 2010 Dec 15;649(1-3):314-9 – reference: 19192936 - Drugs. 2009;69(1):51-69 |
SSID | ssj0023352 |
Score | 2.1413302 |
Snippet | AIM:To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal(GI) injury with... To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with combined... AIM: To investigate prescribing pattern in low-dose aspirin users and physician awareness of preventing aspirin-induced gastrointestinal (GI) injury with... |
SourceID | pubmedcentral proquest pubmed crossref chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3167 |
SubjectTerms | Ambulatory Care Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Ulcer Agents - therapeutic use Aspirin - administration & dosage Aspirin - adverse effects Attitude of Health Personnel Awareness Brief Cardiovascular Agents - administration & dosage Cardiovascular Agents - adverse effects Chi-Square Distribution China Cytoprotection Drug Prescriptions - statistics & numerical data Drug Utilization - statistics & numerical data Gastrointestinal Hemorrhage - chemically induced Gastrointestinal Hemorrhage - prevention & control Health Care Surveys Health Knowledge, Attitudes, Practice Histamine H2 Antagonists - therapeutic use Hospitals, University Humans L-谷氨酰胺 Practice Patterns, Physicians' - statistics & numerical data Proton Pump Inhibitors - therapeutic use Retrospective Studies 联合保护 肠道损伤 胃肠道 药品不良反应 药物 阿司匹林 预防意识 |
Title | Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications |
URI | http://lib.cqvip.com/qk/84123X/201224/42509230.html https://www.ncbi.nlm.nih.gov/pubmed/22791953 https://www.proquest.com/docview/1024934385 https://pubmed.ncbi.nlm.nih.gov/PMC3386331 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6F8sILAnGlHDIS-4Aip7H39GOSJqqQQDy0UuiLtbY3RwU2tDGV-EX8TGbWR44WBEjRKt5Lib_x7MzuzGdC3pggE9oy64tBInxuUuUbKYXPEh1lTNpMOnb-9x_kyRl_NxOzTufnVtRSuU766Y9b80r-B1WoA1wxS_YfkG0nhQr4DvhCCQhD-VcYfywwBPIa87lQYWHwcs3IhJmHeIa-yn1wuks85F-Yq_VlgfQQ8FTnjmvjAm5oE3z-BVxki5wBjrcB44ncsfvWhl5twtIJpyNNI0knikaC6jGdaKoZfvBLSIcD16SoFnQi6PCYDqGzpNExtkLNaIqtkykdjWk0dKNGdBS4PpJqhcN1RHUbZgse88LHone-LHvuary0cDkre59AQ-EFxqfm0F6UoA1757ZekusdDQwNkU2GeKWEcfsU7MpqIbauLgTNCp0qaqebmrtsUrFrPYz5_VtrOhhJ4W3rBXLvAMjXF4v-90D3VyHvb0busHCDahuALTy4Q-6GSrmAALcvVLv2mLnmztXrX14diOP0R_uTI4nHssgX3-Be7RpDNzyc_UDdLcvn9AG5X7ss3rCSv4ekY_NHZIWy57Wy5xVzbyN73p7sefuy51Wy56HseY3seRvZ87Zk7zE5m05Oxyd-_doOP-VhuPZlEERzNodSJmA8csZSJlWYJsIIIdQ8S-aZHQirEm4izmUKwxLBlFEZS3Hb8Ak5yIvcPiOekUZZjQzggeGRTk1gLIwwmUrQ95ddctjey_hrRc8SN1B1yVFzc-O0JrzH9658jsHxRWhigCYGaGKAJkZouuRtO6KZ7fd9Xzd4xaCR8ZjN5LYor2BEyCPGmRZd8rTCr50N-Trx4LpL1A6ybQdke99tyVdLx_rOmJaMBYd_-svPyb3NA_WCHKwvS_sSjOZ18srJ6y9UB7ua |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Poor+awareness+of+preventing+aspirin-induced+gastrointestinal+injury+with+combined+protective+medications&rft.jtitle=%E4%B8%96%E7%95%8C%E8%83%83%E8%82%A0%E7%97%85%E5%AD%A6%E6%9D%82%E5%BF%97%EF%BC%9A%E8%8B%B1%E6%96%87%E7%89%88&rft.au=Ling-Ling+Zhu+Ling-Cheng+Xu+Yan+Chen+Quan+Zhou+Su+Zeng&rft.date=2012-06-28&rft.issn=1007-9327&rft.eissn=2219-2840&rft.volume=18&rft.issue=24&rft.spage=3167&rft.epage=3172&rft_id=info:doi/10.3748%2Fwjg.v18.i24.3167&rft.externalDocID=42509230 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |